X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (46553) 46553
Magazine Article (416) 416
Newsletter (107) 107
Publication (61) 61
Book Chapter (49) 49
Book / eBook (47) 47
Conference Proceeding (23) 23
Book Review (18) 18
Web Resource (18) 18
Newspaper Article (16) 16
Dissertation (12) 12
Transcript (10) 10
Reference (5) 5
Data Set (1) 1
Journal / eJournal (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (42134) 42134
antihypertensive agents - therapeutic use (39302) 39302
hypertension - drug therapy (26503) 26503
male (22902) 22902
female (21669) 21669
middle aged (17790) 17790
hypertension (14990) 14990
aged (14461) 14461
adult (12070) 12070
blood pressure - drug effects (10264) 10264
hypertension - physiopathology (8896) 8896
blood pressure (7421) 7421
risk factors (7368) 7368
treatment outcome (6996) 6996
peripheral vascular disease (6589) 6589
hypertension - complications (6187) 6187
antihypertensive agents - adverse effects (5444) 5444
pharmacology & pharmacy (5281) 5281
animals (5263) 5263
antihypertensive agents - pharmacology (5123) 5123
blood-pressure (4975) 4975
antihypertensive agents - administration & dosage (4815) 4815
drug therapy, combination (4757) 4757
angiotensin-converting enzyme inhibitors - therapeutic use (4392) 4392
medicine, general & internal (4290) 4290
cardiac & cardiovascular systems (3971) 3971
aged, 80 and over (3843) 3843
hypertension - diagnosis (3467) 3467
hypertension - epidemiology (3356) 3356
time factors (3254) 3254
antihypertensive drugs (3178) 3178
mortality (3178) 3178
drug therapy (3163) 3163
prevalence (2989) 2989
calcium channel blockers - therapeutic use (2982) 2982
risk (2854) 2854
double-blind method (2821) 2821
prospective studies (2820) 2820
rats (2797) 2797
follow-up studies (2743) 2743
adrenergic beta-antagonists - therapeutic use (2683) 2683
diuretics - therapeutic use (2580) 2580
care and treatment (2577) 2577
hypertension - therapy (2546) 2546
blood pressure - physiology (2457) 2457
clinical trials as topic (2425) 2425
adolescent (2348) 2348
management (2299) 2299
retrospective studies (2258) 2258
therapy (2214) 2214
medicine & public health (2198) 2198
hypertension - etiology (2126) 2126
antihypertensive agents (2123) 2123
research (2113) 2113
randomized controlled trials as topic (2099) 2099
prevention (2079) 2079
disease (1967) 1967
cardiovascular diseases - prevention & control (1866) 1866
prognosis (1841) 1841
ophthalmology (1794) 1794
tetrazoles - therapeutic use (1794) 1794
age factors (1781) 1781
health aspects (1770) 1770
analysis (1750) 1750
internal medicine (1728) 1728
diuretics (1656) 1656
dose-response relationship, drug (1640) 1640
stroke (1635) 1635
diabetes (1605) 1605
practice guidelines as topic (1580) 1580
cross-sectional studies (1564) 1564
patient compliance (1546) 1546
heart rate - drug effects (1526) 1526
urology & nephrology (1524) 1524
hypertension, pulmonary - drug therapy (1521) 1521
abridged index medicus (1506) 1506
pregnancy (1480) 1480
cardiovascular disease (1427) 1427
blood pressure monitoring, ambulatory (1419) 1419
hypertension - prevention & control (1399) 1399
double-blind (1398) 1398
angiotensin ii type 1 receptor blockers - therapeutic use (1373) 1373
hypertension - blood (1369) 1369
trial (1348) 1348
risk assessment (1313) 1313
renin-angiotensin system - drug effects (1303) 1303
angiotensin (1256) 1256
hydrochlorothiazide - therapeutic use (1249) 1249
cardiovascular diseases (1244) 1244
drug combinations (1231) 1231
diagnosis (1228) 1228
young adult (1214) 1214
child (1211) 1211
vasodilator agents - therapeutic use (1204) 1204
intraocular pressure - drug effects (1198) 1198
drugs (1188) 1188
cardiology (1176) 1176
glaucoma (1171) 1171
angiotensin receptor antagonists (1166) 1166
hemodynamics - drug effects (1165) 1165
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (29) 29
Online Resources - Online (18) 18
Collection Dvlpm't (Acquisitions) - Vendor file (3) 3
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Scarborough Hospital - General (1) 1
St. Michael's Hospital - Stacks (1) 1
UTL at Downsview - May be requested (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (40115) 40115
German (1921) 1921
French (1194) 1194
Russian (1112) 1112
Spanish (700) 700
Japanese (684) 684
Italian (489) 489
Polish (262) 262
Chinese (243) 243
Portuguese (169) 169
Czech (121) 121
Dutch (119) 119
Danish (108) 108
Swedish (108) 108
Hungarian (101) 101
Romanian (85) 85
Norwegian (81) 81
Croatian (47) 47
Ukrainian (47) 47
Hebrew (45) 45
Finnish (43) 43
Bulgarian (31) 31
Serbian (27) 27
Turkish (26) 26
Slovak (14) 14
Korean (9) 9
Lithuanian (9) 9
Bosnian (2) 2
Icelandic (2) 2
Afrikaans (1) 1
Arabic (1) 1
Persian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet (British edition), ISSN 0140-6736, 2011, Volume 378, Issue 9798, pp. 1231 - 1243
Summary Background Although most cardiovascular disease occurs in low-income and middle-income countries, little is known about the use of effective secondary prevention medications in these communities... 
Internal Medicine | STROKE | MEDICINE, GENERAL & INTERNAL | RISK-FACTORS | THERAPY | MYOCARDIAL-INFARCTION | AVAILABILITY | HEART-FAILURE | SELF-REPORT | ACUTE CORONARY SYNDROMES | MEDICINES | VALIDITY | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Data Collection | Secondary Prevention | Stroke - drug therapy | Urban Population | Antihypertensive Agents - therapeutic use | Drug Utilization | Cardiovascular Agents - therapeutic use | Developed Countries | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Rural Population | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Coronary Disease - drug therapy | Adult | Female | Aged | Developing Countries | Platelet Aggregation Inhibitors - therapeutic use | Adrenergic beta-Antagonists - therapeutic use | Care and treatment | Research | Cardiovascular diseases | Health aspects | Cardiovascular agents | Studies | Low income groups | Stroke | Households | Socioeconomic factors | Data collection | Cardiovascular disease | Epidemiology | Economic development | Community | Drug use | Antihypertensive Agents/therapeutic use | Angiotensin-Converting Enzyme Inhibitors/therapeutic use | Cardiovascular Agents/therapeutic use | Coronary Disease/drug therapy | Cardiovascular Diseases/prevention & control | Platelet Aggregation Inhibitors/therapeutic use | Stroke/drug therapy | MEDICIN OCH HÄLSOVETENSKAP | Adrenergic beta-Antagonists/therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use | MEDICAL AND HEALTH SCIENCES
Journal Article
Postgraduate Medical Journal, ISSN 0032-5473, 12/2016, Volume 92, Issue 1094, pp. 726 - 734
An estimated 5.1 million Americans have chronic heart failure and this is expected to increase 25% by 2030. Heart failure is a clinical syndrome that evolves... 
MEDICINE, GENERAL & INTERNAL | INHIBITION | METAANALYSIS | RANDOMIZED-TRIAL | IN-HOSPITAL MORTALITY | DYSFUNCTION | NATRIURETIC PEPTIDE | COMBINATION | EPIDEMIOLOGY | ROSUVASTATIN | URODILATIN | Vasodilator Agents - therapeutic use | Erythropoietin - therapeutic use | United States | Humans | Calcium Channel Blockers - therapeutic use | Heart Failure - physiopathology | Aminobutyrates - therapeutic use | Cardiotonic Agents - therapeutic use | Societies, Medical | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Isosorbide Dinitrate - therapeutic use | Cardiology | Platelet Aggregation Inhibitors - therapeutic use | Digoxin - therapeutic use | Adrenergic beta-Antagonists - therapeutic use | Hematinics - therapeutic use | Fumarates - therapeutic use | Anticoagulants - therapeutic use | Amides - therapeutic use | Antihypertensive Agents - therapeutic use | Evidence-Based Medicine | Heart Failure - drug therapy | Mineralocorticoid Receptor Antagonists - therapeutic use | American Heart Association | Stroke Volume | Cardiovascular Agents - therapeutic use | Hydralazine - therapeutic use | Atrial Natriuretic Factor - therapeutic use | Iron - therapeutic use | Benzazepines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Diuretics - therapeutic use | Tetrazoles - therapeutic use | Peptide Fragments - therapeutic use | Angiotensin Receptor Antagonists - therapeutic use | Drug Combinations | Practice Guidelines as Topic | Heart failure | Care and treatment | Usage | Analysis | Americans | Diagnosis | Cardiac output | Health aspects | Evidence-based medicine
Journal Article
Current Medicinal Chemistry, ISSN 0929-8673, 08/2015, Volume 22, Issue 24, pp. 2819 - 2857
Heterocyclic N-oxides have emerged as potent compounds with anticancer, antibacterial, antihypertensive, antiparasitic, anti-HIV, anti-inflammatory,... 
Antichagasic agents | Heterocyclic N-oxides | Bioisosteres | Factor xa inhibitors | Antimalarials | Hypoxia | Nitric oxide mimics | Coagulation cascade direct thrombin inhibitors | hypoxia | TRANSITION-METAL CATALYSIS | BETA-AMINOESTER CLASS | CHEMISTRY, MEDICINAL | ACTIVATED PROTEIN-KINASE | antichagasic agents | K-ATP CHANNELS | BIOCHEMISTRY & MOLECULAR BIOLOGY | antimalarials | HUMAN-LEUKOCYTE ELASTASE | coagulation cascade direct thrombin inhibitors | CARBON BOND FORMATION | 1,3-DIOXIDE CORE SCAFFOLDS | HIV-1 ENTRY INHIBITORS | PHARMACOLOGY & PHARMACY | bioisosteres | factor Xa inhibitors | LONG-TERM POTENTIATION | FACTOR XA INHIBITOR | nitric oxide mimics | Anti-HIV Agents - pharmacology | Neuroprotective Agents - therapeutic use | Antihypertensive Agents - pharmacology | Humans | Antineoplastic Agents - therapeutic use | Herbicides - pharmacology | Antihypertensive Agents - therapeutic use | Anti-Bacterial Agents - therapeutic use | Fibrinolytic Agents - pharmacology | Cyclic N-Oxides - therapeutic use | Animals | Neuroprotective Agents - pharmacology | Cyclic N-Oxides - pharmacology | Protein Kinase Inhibitors - therapeutic use | Fibrinolytic Agents - therapeutic use | Anti-HIV Agents - therapeutic use | Anti-Bacterial Agents - pharmacology | Antineoplastic Agents - pharmacology | Protein Kinase Inhibitors - pharmacology
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 01/2017, Volume 2017, Issue 1, p. CD002003
Background Beta‐blockers refer to a mixed group of drugs with diverse pharmacodynamic and pharmacokinetic properties. They have shown long‐term beneficial... 
Hypertension | Kidney disease | Treatment: pharmacological | Stroke | Angiotensin Receptor Antagonists | Pharmacological Therapies | Heart Arrest | Atenolol | Randomized Controlled Trials as Topic | General Pharmacotherapies | Calcium Channel Blockers | Coronary Disease | Adrenergic beta‐Antagonists | Diuretics | Beta‐adrenergic blocking agents | Antihypertensive Agents | Heart & circulation | Medicine General & Introductory Medical Sciences | Treatment of essential Hypertension | Angiotensin Receptor Antagonists [therapeutic use] | Antihypertensive Agents [adverse effects; therapeutic use] | NITRIC-OXIDE RELEASE | Humans | Middle Aged | Calcium Channel Blockers [therapeutic use] | MEDICINE, GENERAL & INTERNAL | END-POINT REDUCTION | Adult | CENTRAL BLOOD-PRESSURE | Hypertension [drug therapy; mortality] | ANTIHYPERTENSIVE TREATMENT | Heart Arrest [prevention & control] | CHRONIC HEART-FAILURE | Diuretics [therapeutic use] | Coronary Disease [prevention & control] | RANDOMIZED-TRIAL | CARDIOVASCULAR MORBIDITY | CALCIUM-CHANNEL BLOCKERS | DIRECT RENIN INHIBITOR | Atenolol [therapeutic use] | Aged | Stroke [prevention & control] | Adrenergic beta-Antagonists [adverse effects; therapeutic use] | CORONARY-ARTERY-DISEASE | Stroke - prevention & control | Calcium Channel Blockers - therapeutic use | Hypertension - drug therapy | Antihypertensive Agents - therapeutic use | Antihypertensive Agents - adverse effects | Coronary Disease - prevention & control | Atenolol - therapeutic use | Heart Arrest - prevention & control | Adrenergic beta-Antagonists - adverse effects | Diuretics - therapeutic use | Hypertension - mortality | Angiotensin Receptor Antagonists - therapeutic use | Adrenergic beta-Antagonists - therapeutic use
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 04/2018, Volume 2018, Issue 4, p. CD001841
...: What class of drug to use first‐line? This review attempted to answer that question. Objectives To quantify the mortality and morbidity effects from different first... 
Hypertension | Kidney disease | Treatment: pharmacological | Stroke | Sodium Chloride Symporter Inhibitors | Pharmacological Therapies | Angiotensin‐Converting Enzyme Inhibitors | Randomized Controlled Trials as Topic | General Pharmacotherapies | Calcium Channel Blockers | Coronary Disease | Adrenergic beta‐Antagonists | Antihypertensive Agents | Heart & circulation | Thiazides | Medicine General & Introductory Medical Sciences | Treatment of essential Hypertension | Angiotensin-Converting Enzyme Inhibitors [therapeutic use] | Antihypertensive Agents [adverse effects; therapeutic use] | Coronary Disease [prevention & control] | Humans | ELDERLY PROGRAM SHEP | CONVERTING-ENZYME-INHIBITION | Sodium Chloride Symporter Inhibitors [therapeutic use] | Adrenergic beta-Antagonists [therapeutic use] | EUROPEAN-WORKING-PARTY | PROSPECTIVELY-DESIGNED OVERVIEWS | Calcium Channel Blockers [therapeutic use] | SERUM URIC-ACID | MEDICINE, GENERAL & INTERNAL | AUSTRALIAN THERAPEUTIC TRIAL | HIGH-BLOOD-PRESSURE | ISOLATED SYSTOLIC HYPERTENSION | PLACEBO-CONTROLLED TRIAL | Stroke [prevention & control] | CORONARY-HEART-DISEASE | Hypertension [drug therapy; mortality] | Stroke - prevention & control | Middle Aged | Calcium Channel Blockers - therapeutic use | Hypertension - drug therapy | Sodium Chloride Symporter Inhibitors - therapeutic use | Antihypertensive Agents - therapeutic use | Antihypertensive Agents - adverse effects | Coronary Disease - prevention & control | Thiazides - adverse effects | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Hypertension - mortality | Adrenergic beta-Antagonists - therapeutic use | Thiazides - therapeutic use
Journal Article